=====================
Kali, Inc. (KALY)
Alert Price: $0.0062
Float: 6.74M
Price Target: $0.05
(Goldman Small Cap Research)
Website | Recent News
========================
Members,
Nothing moves a stock like acquisition news.
In fact just yesterday, Fitbit's stock soared amid a report that Alphabet's Google is in talks to buy the smartwatch maker.
That being said, you'll be happy to know that out latest trade idea has some acquisition news of their own, and it has been reported that this news will be released tomorrow!
Please turn your immediate attention to Kali, Inc. (KALY).
KALY To Review Acquisition Interest In Its Cannabis Extract Biopharmaceutical Technology Tomorrow
Yesterday, KALY managment announced plans to issue an update this Wednesday, October 30th, 2019 regarding the recent acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology. KALY CEO Frederick Ferri commented on the acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology indicating that the interest stems from industry investors recognizing that KALY’s technology is undervalued.
In the fourth quarter of last year, 2018, KALY acquired NCMB. NCMB owns and operates a US Patented Cannabis Extraction Process. In NCMB’s four years of operations prior to the acquisition by KALY, NCMB established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025.
In addition to KALY’s ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY’s U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.
Since the last biopharmaceuticals strategy update, KALY has made substantial strides. KALY has since engaged with a major university to initiate a next round of evaluations and testing of its COPD treatment. The university program is anticipated to kickoff soon and the company plans to issue periodic updates as the program proceeds.
KALY has also made recent progress in advancing the development of its other treatments. The advances have been made possible by new partnerships. Announcements about the new partnerships are coming soon.
KALY has implemented a sustainable strategy to develop cannabis extracts from its US Patented Cannabis Extraction Process to treat a variety of specific health issues. In light of the long-term commitment to the biopharmaceutical development process and the corresponding requirement for continuous fund raising through the process, KALY has implemented a parallel business strategy to more immediately monetize its patented intellectual property through consumer applications of its technology. KALY has issued a limited license of its patented process to Puration, Inc. (PURA) for the infusion of cannabis extracts into beverages. KALY has also developed and is selling its own line of CBD infused candies under the brand name Hemp4mula. The candies are for sale on North American Cannabis Holdings (USMJ) eCommerce site, www.usmj.com. KALY has also signed direct cannabis extraction contracts with hemp farming operations with a total value so far of $15 million. KALY management recently announced an anticipated jump in revenue in Q4 2019 related to the company’s CBD extraction contracts with hemp farming operations currently underway now that the hemp harvest season is in full swing.
Ferri plans to keep shareholders update regularly on the current interest expressed in the possible acquisition of KALY’s Cannabis Biopharmaceutical Extract Technology.
About Kali-Extracts Inc.
Kali-Extracts, Inc. is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies to include the licensing of its patented cannabis extraction technology to multiple companies in the wellness and pharmaceutical industries. With promising preclinical data along with development and commercial agreements behind it, Kali-Extracts seeks to commercialize its unique and valuable IP targeting multi-billion-dollar markets.
To stay abreast of the latest developments and learn more about the company visit www.kali-extracts.com/.
KALY is one of the most attractive companies we've come across in quite some time.
With the help of their game changing CBD extraction process, KALY is raking in some big-time revenue numbers!
KALY Anticipates Q4 Revenue Jump From CBD Extraction Contracts
Earlier this month, KALY announced an anticipated jump in revenue in Q4 2019 related to the company’s CBD extraction contracts with hemp farming operations currently underway now that the hemp harvest season is in full swing. The company has announced hemp extraction contracts worth a potential $15 million in revenue. While not all that revenue will be realized in one quarter, management still anticipates a substantial jump in revenue in Q4 over previous recent quarters.
KALY’s financial growth is impressive. For the first six months of 2019, revenue jumped by 250% to $165,000, up from $46,000 in the corresponding period in 2018. Plus, the Company recorded enviable operating profit of $70,000---highly unusual for a company of its size. With new hemp farming CBD extraction contracts in hand, the top-line growth in the second half of the year could be substantially higher. As noted above, the Company’s innovative extraction technology is already bearing significant fruit while revenue streams are diversified by multiple CBD-infused wellness channels and products.
There Is An Exploding Demand For KALY's CBD Extraction Services
Announced what it referred to as “exploding” demand for its CBD extraction services. KALY has already begun harvesting its first hemp crop in the state of New York signed under a consignment contract worth a potential $5 million. Word is out on KALY’s process and KALY is receiving what it characterizes as “non-stop” calls for extraction services. “The hemp harvesting season has hit and I think some of the first-time hemp farmers are realizing now that they don’t’ have the equipment to extract CBD from hemp,” said Frederick Ferri, CEO of KALY. “The equipment is expensive and even if you’ve got the funds, good luck finding the equipment now.” The State of New York alone, where KALY is already working, has a reported 18,000 acers of hemp in just the Hudson Valley area. “The extraction infrastructure we have established is mobile. We have the ability to go from farm to farm and extract the raw hemp oil on site to then be sent to a lab for the CBD extraction process,” added Mr. Ferri. “It looks like we are going to be very busy this fall.” KALY is planning on concentrating its CBD extraction services in just the North East this fall and expanding nationwide next year.
KALY Is Cementing Themselves As A Major Player In The $1.4B CBD-Infused Drink Market
It’s safe to say that the cascade of cannabis legislation has sent the world into a constant state of flux. We are witnessing a seismic shift in culture, as cannabis steps out of the black market and into unexpected industries—from big pharma, to beauty, and now to beverages.
According to Zenith Global, the U.S. CBD-infused drinks market will reach an estimated $1.4 billion by 2023, making it one of the fastest-growing segments in the overall industry.
As part of the sole license it has granted to Puration, Inc. (PURA) for use of the KALY U.S. Patented Cannabis Extraction Process for the production of beverages, KALY has recently been engaged by PURA to design a coffee infusion process.
Earlier this month, PURA announced the company will begin producing CBD infused Fair Trade coffee from Kenya:
“Today, PURA is proud to announce entering into an agreement with a Fair Trade producer of coffee in Kenya. Farmers who grow Fair Trade coffee receive a fair price, and their communities and the environment benefit as well. PURA has engaged Kali-Extracts, Inc. (KALY) to design the CBD infusion for ground coffee. PURA anticipates beginning CBD coffee product testing next month. PURA is also in conversations with growers in Ethiopia.”
KALY has implemented a sustainable strategy to develop cannabis extracts from its US Patented Cannabis Extraction Process to treat a variety of specific health issues. KALY has also implemented a parallel business strategy to more immediately monetize its patented intellectual property through consumer applications of its technology. KALY has issued a limited license of its patented process to Puration, Inc. (PURA) for the infusion of cannabis extracts into beverages. KALY has also developed and is selling its own line of CBD infused candies under the brand name Hemp4mula. The candies are for sale on North American Cannabis Holdings (USMJ) eCommerce site, www.usmj.com. KALY has also signed direct cannabis extraction contracts with hemp farming operations with a total value so far of $15 million.
Goldman Small Cap Research Bullish On KALY. Slaps On $0.05 Price Target
+706% Upside From Today's Alert Price
"Already generating major revenue growth and operating profit, a series of near-term revenue and pharmaceutical development milestones by KALY warrant a closer look by investors as these shares could trade to the $0.05 level in the near term." Goldman Small Cap Research
Investment Highlights
KALY appears to be hitting on all cylinders with new contracts, new products, and major milestones in biopharmaceutical product
development.
KALY is in the early innings of leveraging its innovative, patented cannabis extraction technology to generate major revenue in key segments of the hemp-based cannabis industry. Overall, the Brightfield Group projects that Hemp-based CBD products will reach $22B in sales in 2022.
Leveraging an innovative mobile approach, management believes it could generate $20M in an annual revenue run rate for the CBD
extraction service business. Diversifying itsrevenue, KALY also licenses IP to partner CBDinfused food and beverage wellness companies.
KALY is set to advance studies to evaluate its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients WHO estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
Market Outlook
US CBD retail sales are expected to grow 133% in 2019 over 2018 reaching over $1 billion and that continued CBD retail sales may exceed $10 billion by 2026.
According to Zenith Global, the U.S. CBD-infused drinks market will reach an estimated $1.4 billion by 2023, making it one of the fastest-growing segments in the overall industry.
KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024.
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
The Bottom Line
We are anticipating a huge day for KALY
Tomorrow's acquisition update is sure to grab the attention of Wall St.
On top of that, we love KALY's revenue growth, and are extremely excited to see what type of growth it will see in the upcoming quarters.
The Company trades for under a penny a share and has $15 Million in CBD contracts.
This appears to be a no brainer from our point of view.
We are urging all members to start their research on KALY immediately, and consider grabbing up shares at 9:30AM EST!
(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best Regards,
*Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $10000 cash for a 1-week marketing contract for KALY. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
Kali, Inc. (KALY)
Alert Price: $0.0062
Float: 6.74M
Price Target: $0.05
(Goldman Small Cap Research)
Website | Recent News
========================
Members,
Nothing moves a stock like acquisition news.
In fact just yesterday, Fitbit's stock soared amid a report that Alphabet's Google is in talks to buy the smartwatch maker.
That being said, you'll be happy to know that out latest trade idea has some acquisition news of their own, and it has been reported that this news will be released tomorrow!
Please turn your immediate attention to Kali, Inc. (KALY).
KALY To Review Acquisition Interest In Its Cannabis Extract Biopharmaceutical Technology Tomorrow
Yesterday, KALY managment announced plans to issue an update this Wednesday, October 30th, 2019 regarding the recent acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology. KALY CEO Frederick Ferri commented on the acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology indicating that the interest stems from industry investors recognizing that KALY’s technology is undervalued.
In the fourth quarter of last year, 2018, KALY acquired NCMB. NCMB owns and operates a US Patented Cannabis Extraction Process. In NCMB’s four years of operations prior to the acquisition by KALY, NCMB established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025.
In addition to KALY’s ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY’s U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.
Since the last biopharmaceuticals strategy update, KALY has made substantial strides. KALY has since engaged with a major university to initiate a next round of evaluations and testing of its COPD treatment. The university program is anticipated to kickoff soon and the company plans to issue periodic updates as the program proceeds.
KALY has also made recent progress in advancing the development of its other treatments. The advances have been made possible by new partnerships. Announcements about the new partnerships are coming soon.
KALY has implemented a sustainable strategy to develop cannabis extracts from its US Patented Cannabis Extraction Process to treat a variety of specific health issues. In light of the long-term commitment to the biopharmaceutical development process and the corresponding requirement for continuous fund raising through the process, KALY has implemented a parallel business strategy to more immediately monetize its patented intellectual property through consumer applications of its technology. KALY has issued a limited license of its patented process to Puration, Inc. (PURA) for the infusion of cannabis extracts into beverages. KALY has also developed and is selling its own line of CBD infused candies under the brand name Hemp4mula. The candies are for sale on North American Cannabis Holdings (USMJ) eCommerce site, www.usmj.com. KALY has also signed direct cannabis extraction contracts with hemp farming operations with a total value so far of $15 million. KALY management recently announced an anticipated jump in revenue in Q4 2019 related to the company’s CBD extraction contracts with hemp farming operations currently underway now that the hemp harvest season is in full swing.
Ferri plans to keep shareholders update regularly on the current interest expressed in the possible acquisition of KALY’s Cannabis Biopharmaceutical Extract Technology.
About Kali-Extracts Inc.
Kali-Extracts, Inc. is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies to include the licensing of its patented cannabis extraction technology to multiple companies in the wellness and pharmaceutical industries. With promising preclinical data along with development and commercial agreements behind it, Kali-Extracts seeks to commercialize its unique and valuable IP targeting multi-billion-dollar markets.
To stay abreast of the latest developments and learn more about the company visit www.kali-extracts.com/.
KALY is one of the most attractive companies we've come across in quite some time.
With the help of their game changing CBD extraction process, KALY is raking in some big-time revenue numbers!
KALY Anticipates Q4 Revenue Jump From CBD Extraction Contracts
Earlier this month, KALY announced an anticipated jump in revenue in Q4 2019 related to the company’s CBD extraction contracts with hemp farming operations currently underway now that the hemp harvest season is in full swing. The company has announced hemp extraction contracts worth a potential $15 million in revenue. While not all that revenue will be realized in one quarter, management still anticipates a substantial jump in revenue in Q4 over previous recent quarters.
KALY’s financial growth is impressive. For the first six months of 2019, revenue jumped by 250% to $165,000, up from $46,000 in the corresponding period in 2018. Plus, the Company recorded enviable operating profit of $70,000---highly unusual for a company of its size. With new hemp farming CBD extraction contracts in hand, the top-line growth in the second half of the year could be substantially higher. As noted above, the Company’s innovative extraction technology is already bearing significant fruit while revenue streams are diversified by multiple CBD-infused wellness channels and products.
There Is An Exploding Demand For KALY's CBD Extraction Services
Announced what it referred to as “exploding” demand for its CBD extraction services. KALY has already begun harvesting its first hemp crop in the state of New York signed under a consignment contract worth a potential $5 million. Word is out on KALY’s process and KALY is receiving what it characterizes as “non-stop” calls for extraction services. “The hemp harvesting season has hit and I think some of the first-time hemp farmers are realizing now that they don’t’ have the equipment to extract CBD from hemp,” said Frederick Ferri, CEO of KALY. “The equipment is expensive and even if you’ve got the funds, good luck finding the equipment now.” The State of New York alone, where KALY is already working, has a reported 18,000 acers of hemp in just the Hudson Valley area. “The extraction infrastructure we have established is mobile. We have the ability to go from farm to farm and extract the raw hemp oil on site to then be sent to a lab for the CBD extraction process,” added Mr. Ferri. “It looks like we are going to be very busy this fall.” KALY is planning on concentrating its CBD extraction services in just the North East this fall and expanding nationwide next year.
KALY Is Cementing Themselves As A Major Player In The $1.4B CBD-Infused Drink Market
It’s safe to say that the cascade of cannabis legislation has sent the world into a constant state of flux. We are witnessing a seismic shift in culture, as cannabis steps out of the black market and into unexpected industries—from big pharma, to beauty, and now to beverages.
According to Zenith Global, the U.S. CBD-infused drinks market will reach an estimated $1.4 billion by 2023, making it one of the fastest-growing segments in the overall industry.
As part of the sole license it has granted to Puration, Inc. (PURA) for use of the KALY U.S. Patented Cannabis Extraction Process for the production of beverages, KALY has recently been engaged by PURA to design a coffee infusion process.
Earlier this month, PURA announced the company will begin producing CBD infused Fair Trade coffee from Kenya:
“Today, PURA is proud to announce entering into an agreement with a Fair Trade producer of coffee in Kenya. Farmers who grow Fair Trade coffee receive a fair price, and their communities and the environment benefit as well. PURA has engaged Kali-Extracts, Inc. (KALY) to design the CBD infusion for ground coffee. PURA anticipates beginning CBD coffee product testing next month. PURA is also in conversations with growers in Ethiopia.”
KALY has implemented a sustainable strategy to develop cannabis extracts from its US Patented Cannabis Extraction Process to treat a variety of specific health issues. KALY has also implemented a parallel business strategy to more immediately monetize its patented intellectual property through consumer applications of its technology. KALY has issued a limited license of its patented process to Puration, Inc. (PURA) for the infusion of cannabis extracts into beverages. KALY has also developed and is selling its own line of CBD infused candies under the brand name Hemp4mula. The candies are for sale on North American Cannabis Holdings (USMJ) eCommerce site, www.usmj.com. KALY has also signed direct cannabis extraction contracts with hemp farming operations with a total value so far of $15 million.
Goldman Small Cap Research Bullish On KALY. Slaps On $0.05 Price Target
+706% Upside From Today's Alert Price
"Already generating major revenue growth and operating profit, a series of near-term revenue and pharmaceutical development milestones by KALY warrant a closer look by investors as these shares could trade to the $0.05 level in the near term." Goldman Small Cap Research
Investment Highlights
KALY appears to be hitting on all cylinders with new contracts, new products, and major milestones in biopharmaceutical product
development.
KALY is in the early innings of leveraging its innovative, patented cannabis extraction technology to generate major revenue in key segments of the hemp-based cannabis industry. Overall, the Brightfield Group projects that Hemp-based CBD products will reach $22B in sales in 2022.
Leveraging an innovative mobile approach, management believes it could generate $20M in an annual revenue run rate for the CBD
extraction service business. Diversifying itsrevenue, KALY also licenses IP to partner CBDinfused food and beverage wellness companies.
KALY is set to advance studies to evaluate its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients WHO estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
Market Outlook
US CBD retail sales are expected to grow 133% in 2019 over 2018 reaching over $1 billion and that continued CBD retail sales may exceed $10 billion by 2026.
According to Zenith Global, the U.S. CBD-infused drinks market will reach an estimated $1.4 billion by 2023, making it one of the fastest-growing segments in the overall industry.
KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024.
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
The Bottom Line
We are anticipating a huge day for KALY
Tomorrow's acquisition update is sure to grab the attention of Wall St.
On top of that, we love KALY's revenue growth, and are extremely excited to see what type of growth it will see in the upcoming quarters.
The Company trades for under a penny a share and has $15 Million in CBD contracts.
This appears to be a no brainer from our point of view.
We are urging all members to start their research on KALY immediately, and consider grabbing up shares at 9:30AM EST!
(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best Regards,
*Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $10000 cash for a 1-week marketing contract for KALY. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.